Aprea Therapeutics Inc logo

APRE - Aprea Therapeutics Inc News Story

$4.3 0.0  0.9%

Last Trade - 07/05/21

Small Cap
Market Cap £65.2m
Enterprise Value £1.49m
Revenue £n/a
Position in Universe 5228th / 6858

BUZZ-Aprea Therapeutics: Jumps on 'orphan drug' tag for cancer treatment

Thu 8th April, 2021 4:55pm
** Drug developer's  APRE.O  shares jump 13.6% to $5.50
    ** Co says U.S. FDA granted "orphan drug" designation to its
experimental drug, eprenetapopt, for treatment of adult acute
myeloid leukemia, a type of cancer that affects bone marrow and
blood [https://refini.tv/3dOY8pA
    ** Orphan status is granted to treatments for rare diseases
or disorders that affect fewer than 200,000 people in the United
    ** In December, eprenetapopt in combination with APRE
chemotherapy drug azacitidine did not meet main goal of a
late-stage trial in patients with a type of cancer in which
blood cells in bone marrow do not mature  urn:newsml:reuters.com:*:nL4N2J81PS 
    ** Eprenetapopt has been granted 'fast track' designation by
    ** Stock up ~11% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.